PURPOSE: To report the results from a prospective study of a series of locoregionally advanced head-and-neck cancer patients treated with platinum-based chemotherapy and intensity-modulated radiotherapy and to discuss the findings of their pre-/mid-treatment [(18)F]-misonidazole ((18)F-FMISO) positron emission tomography (PET) scans. METHODS AND MATERIALS: A total of 28 patients agreed to participate in this study. Of these 28 patients, 20 (90% with an oropharyngeal primary cancer) were able to undergo the requirements of the protocol. Each patient underwent four PET scans: one pretreatment fluorodeoxyglucose PET/computed tomography scan, two pretreatment (18)F-FMISO PET/computed tomography scans, and a third (18)F-FMISO PET (mid-treatment) scan performed 4 weeks after the start of chemoradiotherapy. The (18)F-FMISO PET scans were acquired 2-3 h after tracer administration. Patients were treated with 2-3 cycles of platinum-based chemotherapy concurrent with definitive intensity-modulated radiotherapy. RESULTS: A heterogeneous distribution of (18)F-FMISO was noted in the primary and/or nodal disease in 90% of the patients. Two patients had persistent detectable hypoxia on their third mid-treatment (18)F-FMISO PET scan. One patient experienced regional/distant failure but had no detectable residual hypoxia on the mid-treatment (18)F-FMISO PET scan. CONCLUSION: Excellent locoregional control was observed in this series of head-and-neck cancer patients treated with concurrent platinum-based chemotherapy and intensity-modulated radiotherapy despite evidence of detectable hypoxia on the pretreatment (18)F-FMISO PET/computed tomography scans of 18 of 20 patients. In this prospective study, neither the presence nor the absence of hypoxia, as defined by positive (18)F-FMISO findings on the mid-treatment PET scan, correlated with patient outcome. The results of this study have confirmed similar results reported previously.
PURPOSE: To report the results from a prospective study of a series of locoregionally advanced head-and-neck cancerpatients treated with platinum-based chemotherapy and intensity-modulated radiotherapy and to discuss the findings of their pre-/mid-treatment [(18)F]-misonidazole ((18)F-FMISO) positron emission tomography (PET) scans. METHODS AND MATERIALS: A total of 28 patients agreed to participate in this study. Of these 28 patients, 20 (90% with an oropharyngeal primary cancer) were able to undergo the requirements of the protocol. Each patient underwent four PET scans: one pretreatment fluorodeoxyglucose PET/computed tomography scan, two pretreatment (18)F-FMISO PET/computed tomography scans, and a third (18)F-FMISO PET (mid-treatment) scan performed 4 weeks after the start of chemoradiotherapy. The (18)F-FMISO PET scans were acquired 2-3 h after tracer administration. Patients were treated with 2-3 cycles of platinum-based chemotherapy concurrent with definitive intensity-modulated radiotherapy. RESULTS: A heterogeneous distribution of (18)F-FMISO was noted in the primary and/or nodal disease in 90% of the patients. Two patients had persistent detectable hypoxia on their third mid-treatment (18)F-FMISO PET scan. One patient experienced regional/distant failure but had no detectable residual hypoxia on the mid-treatment (18)F-FMISO PET scan. CONCLUSION: Excellent locoregional control was observed in this series of head-and-neck cancerpatients treated with concurrent platinum-based chemotherapy and intensity-modulated radiotherapy despite evidence of detectable hypoxia on the pretreatment (18)F-FMISO PET/computed tomography scans of 18 of 20 patients. In this prospective study, neither the presence nor the absence of hypoxia, as defined by positive (18)F-FMISO findings on the mid-treatment PET scan, correlated with patient outcome. The results of this study have confirmed similar results reported previously.
Authors: D Rischin; L Peters; R Hicks; P Hughes; R Fisher; R Hart; M Sexton; I D'Costa; R von Roemeling Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: D J Lee; A Trotti; S Spencer; R Rostock; C Fisher; R von Roemeling; E Harvey; E Groves Journal: Int J Radiat Oncol Biol Phys Date: 1998-11-01 Impact factor: 7.038
Authors: M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel Journal: Radiother Oncol Date: 1993-01 Impact factor: 6.280
Authors: Jerry L Barker; Bonnie S Glisson; Adam S Garden; Adel K El-Naggar; William H Morrison; K Kian Ang; K S Clifford Chao; Gary Clayman; David I Rosenthal Journal: Cancer Date: 2003-12-01 Impact factor: 6.860
Authors: A Becker; G Hänsgen; M Bloching; C Weigel; C Lautenschläger; J Dunst Journal: Int J Radiat Oncol Biol Phys Date: 1998-08-01 Impact factor: 7.038
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Mark W Dewhirst; Donald E Thrall; Gregory Palmer; Thies Schroeder; Zeljko Vujaskovic; H Cecil Charles; James Macfall; Terence Wong Journal: Int J Hyperthermia Date: 2010 Impact factor: 3.914
Authors: Mireia Crispin-Ortuzar; Aditya Apte; Milan Grkovski; Jung Hun Oh; Nancy Y Lee; Heiko Schöder; John L Humm; Joseph O Deasy Journal: Radiother Oncol Date: 2017-12-19 Impact factor: 6.280